SUSMED,Inc.
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Income Statement | |||
| Revenue | ¥317M | ¥531M | ¥343M |
| Gross Profit | ¥306M | ¥523M | ¥331M |
| Operating Income | -¥229M | -¥48M | -¥365M |
| Pretax Income | -¥229M | -¥48M | -¥365M |
| Net Income | -¥233M | -¥51M | -¥357M |
| EPS | -¥15.90 | -¥3.09 | -¥21.41 |
| Operating Margin | -72.32% | -9.10% | -106.54% |
| Balance Sheet | |||
| Total Assets | ¥4,944M | ¥5,101M | ¥4,932M |
| Total Equity | ¥4,850M | ¥4,871M | ¥4,604M |
| Total Liabilities | ¥93M | ¥230M | ¥328M |
| Cash | ¥4,904M | ¥5,049M | ¥4,847M |
| Interest-bearing Debt | - | - | - |
| Equity Ratio | 98.11% | 95.48% | 93.35% |
| D/E Ratio | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||
| Operating CF | -¥165M | ¥101M | -¥231M |
| Investing CF | -¥20M | -¥18M | -¥9M |
| Financing CF | ¥3,463M | ¥62M | ¥37M |
| Free CF | -¥178M | ¥82M | -¥240M |
| Efficiency | |||
| ROE | -4.81% | -1.04% | -7.76% |
| ROA | -4.72% | -0.99% | -7.25% |
Latest IR Information
-
(Correction) Timely Disclosure: Partial Correction of the Notice Regarding Issuance of New Shares as Restricted Stock-Based Remuneration
A correction was made to the notice regarding issuance of new shares as restricted stock-based remuneration due to an error in the stated total amount of monetary compensation claims. After correction, the total monetary compensation claims to be paid are...
Read more -
Notice of Issuance of New Shares as Restricted Stock Compensation
Resolved to issue new shares as restricted stock compensation for directors. 73,200 shares allocated to four recipients, issue price 443 yen, payment due date 2026/10/19. Restriction period set from 2026/10/19 to 2029/10/18; conditions for forfeiture upon resignation and conditions for...
Read more -
Notice Regarding Reallocation of Funds Usage
Reason for change: reallocation of funds for R&D in the DTx product business, personnel investments, and office expansion. New disclosure targets include increases in R&D funding, increases in personnel investments, and increased office expansion costs. Expected impact going forward is...
Read more -
Notice Regarding the Start of Sales of Medcle, an App for Insomnia Treatment
Approval for insurance coverage and start of sales for the treatment app Medcle planned to commence in June 2026; sales will be handled in-house; focus on progress of the development pipeline and trends in sales partnerships.
Read more -
Notice of Agreement on Termination of Exclusive Sales Agreement for Medcle, an App for Insomnia Disorder
Milestone compensation of 200 million yen confirmed; termination agreement for the exclusive sales contract signed. Sales will continue to be recognized by the company on a standalone basis after termination, with minimal impact. Future consideration of other partnerships.
Read more -
Notice of Headquarters Relocation Date
Relocate headquarters to 1-9 Nihonbashi Honcho, Chuo-ku, Tokyo. Relocation date is Monday, September 14, 2026, with the new address at Nihonbashi Honcho M-SQUARE 3F. The impact on performance is factored into the earnings guidance for the fiscal year ending June...
Read more
Latest News (5 items)
Company Information
About
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
